157 related articles for article (PubMed ID: 32264883)
1. Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS).
Annemans L; Azuri J; Al-Rasadi K; Al-Zakwani I; Daclin V; Mercier F; Danchin N
Lipids Health Dis; 2020 Apr; 19(1):64. PubMed ID: 32264883
[TBL] [Abstract][Full Text] [Related]
2. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
[TBL] [Abstract][Full Text] [Related]
3. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.
Ferrieres J; De Ferrari GM; Hermans MP; Elisaf M; Toth PP; Horack M; Brudi P; Lautsch D; Bash LD; Baxter CA; Ashton V; Ambegaonkar B; Gitt AK
Eur J Prev Cardiol; 2018 Dec; 25(18):1966-1976. PubMed ID: 30335504
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study.
Blom DJ; Almahmeed W; Al-Rasadi K; Azuri J; Daclin V; Kayikcioglu M; Mercier F; Ruiz AJ; Santos RD;
J Clin Lipidol; 2019; 13(4):594-600. PubMed ID: 31208705
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
[TBL] [Abstract][Full Text] [Related]
6. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
7. FACTORS INFLUENCING ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS IN MEXICO: THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY.
Bello-Chavolla OY; Aguilar-Salinas CA
Rev Invest Clin; 2019; 71(6):408-416. PubMed ID: 31823964
[TBL] [Abstract][Full Text] [Related]
8. Lipid management across Europe in the real-world setting: a rapid evidence review.
Barrios V; Soronen J; Carter AM; Anastassopoulou A
Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
[TBL] [Abstract][Full Text] [Related]
10. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
Sawant S; Wang N
Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J
BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II.
Poh KK; Ambegaonkar B; Baxter CA; Brudi P; Buddhari W; Chiang FT; Horack M; Jang Y; Johnson B; Lautsch D; Sawhney J; Vyas A; Yan BP; Gitt AK
Eur J Prev Cardiol; 2018 Dec; 25(18):1950-1963. PubMed ID: 30198749
[TBL] [Abstract][Full Text] [Related]
13. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
14. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry.
Ferrari R; Ford I; Greenlaw N; Tardif JC; Tendera M; Abergel H; Fox K; Hu D; Shalnova S; Steg PG;
Eur J Prev Cardiol; 2015 Aug; 22(8):1056-65. PubMed ID: 25147344
[TBL] [Abstract][Full Text] [Related]
15. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).
Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S
J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
[TBL] [Abstract][Full Text] [Related]
17. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
18. The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study.
Blom DJ; Santos RD; Daclin V; Mercier F; Ruiz AJ; Danchin N;
Eur J Prev Cardiol; 2020 Sep; 27(13):1403-1411. PubMed ID: 31533447
[TBL] [Abstract][Full Text] [Related]
19. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
